For the Media
Dr. Philip Greenberg is a member of Fred Hutch's Clinical Research Division and is head of the Program in Immunology. His laboratory performed some of the earliest studies focused on how immune T cells can recognize and eliminate malignant cells in the context of progressing tumors and has developed technologies to isolate and expand functional, target (antigen)-specific T cells to numbers large enough to be effective when given to patients as adoptive immune-boosting therapy.
Overview of Philip Greenberg's Research Focus
Internationally recognized as a leader in the cancer immunology field, Philip Greenberg has trained more than 30 investigators who have gone on to develop independent research careers, including many who have also become leaders in immunology fields.
Philip Greenberg - Brief Curriculum Vitae
Appointments, affiliations and researcher interests
Program in Immunology
Researchers are learning how to empower a patient’s own immune system to do what it does naturally — fight disease. They continue discovering new ways to give the immune cell army the upper hand against cancer and learning how immune cells respond to disease and how to safely enhance immune responses to better control, cure and potentially prevent cancers and other serious diseases.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.